MedRx Cash Flow Statement

Financials in millions JPY. Fiscal year is January - December.

Millions JPY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Income	-802	-930	-1,109	-1,058	-1,106
Depreciation & Amortization	38	45	46	60	55
Loss (Gain) From Sale of Investments	68	-	-	-	-
Other Operating Activities	49	-	-	8	-1
Change in Inventory	-	-1	3	8	-1
Change in Accounts Payable	-	-58	32	52	-4
Change in Other Net Operating Assets	-156	31	-45	7	72
Operating Cash Flow	-803	-913	-1,073	-923	-985
Capital Expenditures	-	-	-1	-2	-39
Other Investing Activities	-3	-	-	-	-
Investing Cash Flow	-3	-	-1	-2	-5
Short-Term Debt Issued	-	-	-	-	50
Long-Term Debt Issued	-	-	-	550	-
Total Debt Issued	-	-	-	550	50
Short-Term Debt Repaid	-	-	-	-50	-
Long-Term Debt Repaid	-	-	-	-550	-
Total Debt Repaid	-	-	-	-600	-
Net Debt Issued (Repaid)	-	-	-	-50	50
Issuance of Common Stock	1,066	1,639	356	865	1,343
Financing Cash Flow	1,066	1,639	356	815	1,393
Foreign Exchange Rate Adjustments	-3	1	9	1	-1
Miscellaneous Cash Flow Adjustments	-1	-1	-	1	-1
Net Cash Flow	256	726	-709	-108	401
Free Cash Flow	-803	-913	-1,074	-925	-1,024
Free Cash Flow Margin	-312.45%	-3148.28%	-1820.34%	-11562.50%	-890.44%
Free Cash Flow Per Share	-18.47	-26.25	-42.34	-43.31	-63.03
Cash Interest Paid	-	-	-	1	-
Cash Income Tax Paid	4	2	2	1	4
Levered Free Cash Flow	-481.63	-569.75	-652.13	-529.75	-696
Unlevered Free Cash Flow	-481.63	-569.75	-652.13	-529.13	-696
Change in Working Capital	-156	-28	-10	67	67

Source: S&P Global Market Intelligence. Standard template. Financial Sources.